FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation

Authors

• Anil Kumar, University of Texas Medical Branch, Galveston, TX
• Saghir Ali, University of Texas Medical Branch, Galveston, TX
• Qiang Shen, LSU Health Sciences Center - New OrleansFollow
• Jia Zhou, University of Texas Medical Branch, Galveston, TX

Document Type

Editorial

Publication Date

7-23-2026

Publication Title

Journal of Medicinal Chemistry

First Page

16135

Last Page

16142

PubMed ID

42489504

Volume

69

Issue

14

Comments

Featured in Faculty Publications Display; September 2026

Rights

Copyright © 2026 American Chemical Society

Recommended Citation

Kumar, Anil; Ali, Saghir; Shen, Qiang; and Zhou, Jia, "FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation" (2026). School of Medicine Faculty Publications. 4904.
https://digitalscholar.lsuhsc.edu/som_facpubs/4904
10.1021/acs.jmedchem.6c02076